The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation

FEMS Yeast Research

Volumn 9, Issue 8, 2009, Pages 1312-1321

  Krasowska, Anna ^a   Murzyn, Anna ^a   Dyjankiewicz, Agnieszka ^a   Łukaszewicz, Marcin ^a   Dziadkowiec, Dorota ^a  

^a UNIVERSITY OF WROC AW   (Poland)

Author keywords

Adhesion; Biofilm; Candida albicans; Hyphae formation; Probiotics

Indexed keywords

ARTICLE; BACTERIUM ADHERENCE; CANDIDA ALBICANS; CONTROLLED STUDY; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS CULTURE; NONHUMAN; SACCHAROMYCES BOULARDII; TEMPERATURE MEASUREMENT;

AEROBIOSIS; ANTIBIOSIS; BIOFILMS; CANDIDA ALBICANS; CELL ADHESION; HUMANS; HYPHAE; MICROSCOPY; MICROSCOPY, ELECTRON, SCANNING; SACCHAROMYCES;

BACTERIA (MICROORGANISMS); CANDIDA ALBICANS; FUNGI; SACCHAROMYCES BOULARDII;

EID: 70350521206     PISSN: 15671356     EISSN: 15671364     Source Type: Journal    
DOI: 10.1111/j.1567-1364.2009.00559.x     Document Type: Article

References (38)

1. Alem MAS, Oteef MDY, Flowers TH Douglas LJ (2006) Production of tyrosol by Candida albicans biofilms and its role in quorum sensing and biofilm development. Eukaryot Cell 5 : 1770 1779.
2. Al-Fattani MA Douglas LJ (2004) Penetration of Candida biofilms by antifungal agents. Antimicrob Agents Ch 48 : 3291 3297.
3. Berg R, Bernasconi P, Fowler D Gautreaux M (1993) Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. J Infect Dis 168 : 1314 1318.
4. Biswas SK Chaffin WL (2005) Anaerobic growth of Candida albicans does not support biofilm formation under similar conditions used for aerobic biofilm. Curr Microbiol 51 : 100 104.
5. Bleichner G, Bléhaut H, Mentec H Moyse D (1997) Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intens Care Med 23 : 517 523.
6. Brandao RL, Castro IM, Bambirra EA, Amaral SC, Fietto LG, Tropia MJM, Neves MJ, dos Santos RG, Gomes NCM Nicoli JR (1998) Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microb 64 : 564 568.
7. Braun BR Johnson AD (1997) Control of filament formation in Candida albicans by the transcriptional repressor TUP1. Science 4 : 105 109.
8. Buts J de Keyser N (2006) Effect of Saccharomyces boulardii on intestinal mucosa. Digest Dis Sci 51 : 1485 1492.
9. Calera JA, Zhao X-J Calderone R (2000) Defective hyphal development and avirulence caused by a deletion of the SSK1 response regulator gene in Candida albicans. Infect Immun 68 : 518 525.
10. Castagliuolo I, Riegler MF, Valenick L, Lamont JT Pothoulakis C (1999) Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67 : 302 307.
11. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T Ghannoum MA (2001) Biofilm formation by the fungal pathogen Candida albicans: development, architecture and drug resistance. J Bacteriol 183 : 5385 5394.
12. Czerucka D Rampal P (2002) Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 4 : 733 739.
13. Czerucka D, Dahan S, Mograbi B, Rossi B Rampal P (2000) Saccharomyces boulardii preserve the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 68 : 5998 6004.
14. Dias RS, Bambirra EA, Silva ME Nicoli JR (1995) Protective effect of Saccharomyces boulardii against the cholera toxin in rats. Braz J Med Res 28 : 323 325.
15. Douglas LJ (2003) Candida biofilms and their role in infection. Trends Microbiol 11 : 30 36.
16. Dumitru R, Hornby JM Nickerson KW (2004) Defined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungal drugs. Antimicrob Agents Ch 48 : 2350 2354.
17. Gillum AM, Tsay EY Kirsch DR (1984) Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 198 : 179 182.
18. Hornby JM, Jensen EC, Lisec AD, Tasto JJ, Jahnke B, Shoemaker R, Dussault P Nickerson KW (2001) Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microb 67 : 2982 2992.
19. Jawhara S Poulain D (2007) Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis. Med Mycol 45 : 691 700.
20. Kumamoto CA Vinces MD (2005) Alternative Candida albicans lifestyles: growth on surfaces. Annu Rev Microbiol 59 : 113 133.
21. Lo H-J, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A Fink GR (1997) Nonfilamentous C. albicans mutants are avirulent. Cell 90 : 939 949.
22. Marteau PR, de Vrese M, Cellier CJ Schrezenmeir J (2001) Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 73 : 430S 436S.
23. McFarland LV, Surawicz CM, Greenberg RN et al 1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotic for Clostridium difficile disease. J Am Med Assoc 271 : 1913 1918.
24. Mosel DD, Dumitru R, Hornby JM, Atkin AL Nickerson KW (2005) Farnesol concentrations required to block germ tube formation in Candida albicans in the presence and absence of serum. Appl Environ Microb 71 : 4938 4940.
25. Noverr MC Huffnagle GB (2004) Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infect Immun 72 : 6206 6210.
26. Penna FJ, Filho LAP, Calcado AC, Junior HR Nicolli JR (2000) Up-to-date clinical and experimental basis for the use of probiotics. J Pediatr 76 : S209 S217.
27. Qamar A, Aboudola S, Warny M, Michetti P, Pothoulakis C, Lamont JT Kelly CP (2001) Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in Mice. Infect Immun 69 : 2762 2765.
28. Ramage G, Saville SP, Wickes BL Lopez-Ribot JL (2002) Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microb 68 : 5459 5463.
29. Sanglard D Odds FC (2002) Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2 : 73 85.
30. Saville SP, Lazzell AL, Monteagudo C Lopez-Ribot JL (2003) Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell 2 : 1053 1060.
31. Saville SP, Lazzell AL, Bryant AP, Fretzen A, Monreal A, Solberg EO, Monteagudo C, Lopez-Ribot JL Milne GT (2006) Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob Agents Ch 50 : 3312 3316.
32. Shepherd MG, Yin CY, Ram SP Sullivan PA (1980) Germ tube induction in Candida albicans. Can J Microbiol 26 : 21 26.
33. Sougioultzis S, Simeonidis S, Ramakrishnan Bhaskar K, Chen X, Anton PM, Keates S, Pothoulakis C Kelly CP (2006) Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-κB-mediated IL-8 gene expression. Biochem Bioph Res Co 343 : 69 76.
34. Surawicz CM, McFarland LV, Greenberg RN et al 2000) The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31 : 1012 1017.
35. Thein ZM, Samaranayake YH Samaranayake LP (2007) In vitro biofilm formation of Candida albicans and non-albicans Candida species under dynamic and anaerobic conditions. Arch Oral Biol 52 : 761 767.
36. Tripathi G, Wiltshire C, Macaskill S, Tournu H, Budge S Brown AJP (2002) Gcn4 co-ordinates morphogenetic and metabolic responses to amino acid starvation in Candida albicans. EMBO J 21 : 5448 5456.
37. Uppuluri P, Mekala S Chaffin WL (2007) Farnesol-mediated inhibition of Candida albicans yeast growth and rescue by diacylglycerol analogue. Yeast 24 : 681 693.
38. Yang Y-L (2003) Virulence factors of Candida species. J Microbiol Immunol Infect 36 : 223 228.